Emil Iii Frei

Emil Iii Frei's AcademicInfluence.com Rankings

Emil Iii Frei

Philosophy

#11328

World Rank

#15590

Historical Rank

Logic

#8140

World Rank

#10136

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Emil Iii Frei Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Emil Iii Frei's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. (2003) (1284)
A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. (1990) (1120)
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. (1988) (640)
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. (1998) (566)
Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. (1974) (465)
Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). (1983) (342)
Preclinical studies and clinical correlation of the effect of alkylating dose. (1988) (201)
Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. (1992) (197)
Combined cyclophosphamide, vincristine, and prednisone therapy of malignant lymphoma (1971) (194)
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. (1989) (177)
Bone marrow autotransplantation for solid tumors--prospects. (1989) (174)
Combination chemotherapy of advanced non-Hodgkin lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP). (1977) (162)
High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. (1980) (157)
Selection bias in clinical trials. (1985) (154)
Neoadjuvant chemotherapy in marginally resectable stage III M0 non‐small cell lung cancer: Long‐term follow‐up in 41 patients (1989) (149)
Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute/the Children's Hospital--study III. (1987) (129)
Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. (1975) (127)
High-dose ifosfamide with mesna uroprotection: a phase I study. (1990) (126)
Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. (1995) (124)
High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. (1977) (118)
A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. (1998) (108)
Phase II study of topotecan in metastatic non-small-cell lung cancer. (1994) (106)
The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. (1998) (101)
Weekly high‐dose methotrexate‐citrovorum factor in osteogenic sarcoma. Pre‐surgical treatment of primary tumor and of overt pulmonary metastases (1977) (93)
High-dose methotrexate in osteogenic sarcoma: a 5-year experience. (1978) (90)
Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). (1997) (90)
Carcinoembryonic antigen: Clinical correlation with chemotherapy for metastatic gastrointestinal cancer (1974) (85)
Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. (1993) (83)
A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. (1990) (82)
Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy. (1983) (81)
An evaluation of the management of patients with cerebral metastases from malignant melanoma (1972) (73)
New multiple‐agent chemotherapy (B‐DOPA) for advanced Hodgkin's disease (1976) (68)
High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. (1998) (65)
Intensive combined modality therapy for limited-stage small-cell lung cancer. (1993) (65)
High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. (1997) (64)
Clinical trials of hydroxyurea in patients with cancer and leukemia (1964) (63)
Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. (1996) (59)
Tumor necrosis factor: still a promising agent. (1989) (56)
Serial studies of cardiac function in patients receiving adriamycin. (1978) (51)
Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. (1999) (51)
Lack of effectiveness of combined 5‐fluorouracil and methyl‐ccnu therapy in advanced colorectal cancer (1977) (44)
Combination chemotherapy with adriamycin‐cyclophosphamide for advanced ovarian carcinoma (1980) (43)
Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens. (1992) (43)
Adriamycin cardiotoxicity. (1980) (40)
High-dose methotrexate in osteogenic sarcoma. (1981) (39)
Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD) (1980) (38)
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. (1999) (35)
High‐dose intravenous and hepatic artery infusions of thymidine (1978) (33)
Survival of patients with localized high‐grade soft tissue sarcoma with multimodality therapy: A matched control study (1983) (32)
Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. (1995) (31)
Chemotherapy for head and neck cancer: progress and controversy in the management of patients with M0 disease. (1989) (31)
A therapeutic trial of maytansine. (1978) (31)
Adjuvant chemotherapy of osteogenic sarcoma: progress and perspectives. (1978) (29)
High-dose methotrexate with citrovorum factor in osteogenic sarcoma--progress report II. (1977) (28)
Improved survival for patients with advanced carcinoma of the head and neck treated with methotrexate‐leucovorin prior to definitive radiotherapy or surgery. (1981) (28)
Prolonged disease-free survival in advanced breast cancer treated with "super-CMF" adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue. (1981) (28)
Multidisciplinary treatment for macrometastatic osteogenic sarcoma. (1976) (27)
Pathology of surgery after induction chemotherapy: an analysis of resectability and locoregional control (1986) (25)
Clinical and scientific considerations in preoperative (neoadjuvant) chemotherapy. (1986) (22)
Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology. (1981) (22)
Combination chemotherapy followed by radiation therapy in patients with regional stage III unresectable non-small cell lung cancer. (1985) (20)
High-dose methotrexate in osteogenic sarcoma adjuvant chemotherapy and limb salvage results. (1981) (19)
Hormonal perturbations in patients with testicular cancer treated with cisplatin (1992) (19)
Tumor oxygenation and radiosensitization by pentoxifylline and a perflubron emulsion carbogen breathing. (1993) (16)
Pharmacokinetics and immediate effects of high-dose carmustine in man. (1986) (15)
The role of high-dose methotrexate with citrovorum factor "rescue" in the treatment of osteogenic sarcoma. (1977) (15)
A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer (2001) (14)
High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age. (1994) (14)
Four patients with myelodysplastic syndrome with translocation (1;7)(p11;p11) including one patient with independent clones del(1)(q22) and t(1;7)(q21;q11) (1988) (13)
New agents and combination chemotherapy of non-Hodgkin's lymphoma. (1975) (13)
Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. (1988) (13)
High-dose combined alkylating agent therapy with autologous stem cell support and chest radiotherapy for limited small-cell lung cancer. (1993) (13)
Decreased tumor oxygenation after cyclophosphamide, reoxygenation and therapeutic enhancement with a perflubron emulsion carbogen breathing. (1993) (11)
The impact of regulations, tradition, and experimental design on clinical cancer trials: report and recommendations resulting from Washington Cancer Trials Conference. (1996) (11)
The clinical cancer researcher--still an embattled species. (1993) (11)
Definition and manipulation of tumor oxygenation (1994) (10)
High‐dose therapy/stem cell support: Comparison of mice and humans (1996) (9)
Phase I trial of combination therapy with PALA and 5-FU. (1981) (9)
Continuous‐infusion cisplatin, 5‐fluorouracil, and bolus methotrexate in the treatment of advanced non‐small cell lung cancer (1992) (9)
Phase I trial of bruceantin. (1979) (9)
Non-small cell lung cancer: novel treatment strategies. (1997) (8)
Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapy. (1986) (8)
Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. (1993) (8)
The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses (1999) (8)
Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo (1991) (8)
High-dose chemotherapy with autologous stem cell support for breast cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience. (1993) (8)
The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy. (1993) (8)
Chemotherapeutic strategies in the multidisciplinary treatment of head and neck cancer. (1988) (8)
Continuous‐infusion cisplatin, 5‐fluorouracil, and leucovorin for advanced non‐small cell lung cancer (1994) (7)
Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome. (2002) (7)
Guidelines, regulations, and clinical research. (1986) (7)
Clinical trials of antitumor agents: experimental design and timeline considerations. (1997) (7)
Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support. (1998) (7)
High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions. (1994) (7)
Chapter 12 – THE TOXICITY OF HIGH-DOSE BCNU WITH AUTOLOGOUS MARROW SUPPORT1 (1981) (6)
GM‐CSF mobilized peripheral blood stem cell autografts: The DFCI/BIH experience (1992) (6)
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Etoposide (CHOPE) for Advanced-Stage Hodgkin's Disease: CALGB 8856 (2001) (6)
Chemotherapy (CAP) prior to radiotherapy (RT) and surgery in marginally resectable stage III M0 non-small cell lung cancer. (1985) (5)
Clinical evaluation of local hyperthermia by focused ultrasound (abstract) (1982) (5)
Quality of life in cancer patients: clinical considerations and perspectives. (1990) (4)
A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies (2001) (4)
5‐Fluorouracil with cytosine arabinoside in metastatic gastrointestinal cancer (1975) (4)
Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study (2005) (3)
Testing for doxorubicin cardiotoxicity. (1979) (3)
Dose response for adjuvant chemotherapy of breast cancer: experimental and clinical considerations. (1989) (2)
GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: Two protocols (1991) (2)
Prolonged survival of renal allograft in rats by methotrexate-albumin conjugates as immunosuppressive therapy. (2008) (2)
Four patients with myelodysplastic syndrome with translocation (1;7)(p11;p11) including one patient with independent clones del(7)q22) [corrected] and t(1;7)(q21;q11) (1988) (2)
Limb preservation in osteogenic sarcoma: a preliminary report. (1977) (2)
P-425 A Phase I trial of extrapleural pneumonectomy and intraoperative,bicavitary, hyperthermic cisplatin lavage with intravenous sodium thiosulfate protection for patients with malignant pleural mesothelioma (2005) (1)
The modulation of alkylating agents. (1991) (1)
Neo-adjuvant infusion Cisplatin, 5-FU and high-dose leucovorin for squamous cell carcinoma of the head and neck (SCCHN): high rates of complete response (CR) and definitive radiotherapy as primary site management (1994) (1)
Neo-Adjuvant Cisplatin, 5-Fluorouracil and high-dose Leucovorin for advanced head and neck cancer : response, toxicity, survival and comparison with historical controls (1991) (1)
Impact of Chemotherapy on Osteogenic Sarcoma (1979) (0)
HIGH DOSE METHOTREXATE (HDM) WITH CITROVORUM (CF) RESCUE IN THE MANAGEMENT OF BONE TUMORS (1974) (0)
ThymidineRequirementsfor the Rescueof PatientsTreated with High-DoseMethotrexat& (2006) (0)
Improved Outcomes From Adding Sequent ia l Pacl i taxe l but Not From Escalat ing Doxorubic in Dose in an Adjuvant Chemotherapy Regimen for Pat ients With Node-Pos i t i ve Pr imary Breast Cancer (2003) (0)
Randomized clinical trials and other approaches in clinical research (1994) (0)
High-Dose Chemotherapy III Breast Cancer (1991) (0)

This paper list is powered by the following services:

Emil Iii Frei's Academic­Influence.com Rankings

Why Is Emil Iii Frei Influential?

Emil Iii Frei's Published Works

Published Works

Emil Iii Frei's AcademicInfluence.com Rankings